Abstract
Primary Sclerosing Cholangitis (PSC) is a chronic cholestatic disease characterized by hepatic inflammation and obliterative fibrosis, resulting in both intra- and extra-hepatic bile duct strictures. End-stage liver disease and bile duct carcinoma represent frequent complications. Incidence and prevalence of PSC in USA have been recently estimated as 0.9 per 100,000 person-years, and 1-6 per 100,000 person-years, respectively. Major diagnostic criteria include the presence of multifocal strictures, beadings of bile ducts, and compatible biochemical profile, once excluded secondary causes of cholangitis. Since the aetiology of PSC remains poorly defined, medical therapy is currently limited to symptom improvement and prolonged survival. Ursodeoxycholic acid (UDCA), corticosteroids and immunosuppressants have been proposed alone or in combination to improve the clinical outcome. In selected cases, surgical or endoscopic procedures need to be considered. Orthotopic liver transplantation (OLT) is at the moment the only definitive approach although disease relapse has been reported In this article the state of the art in PSC treatment and future promises in this field are reviewed.
Keywords: Liver, cirrhosis, inflammation, UDCA, immunosuppressant, IBD, cholestasis, biliary obstruction
Current Medicinal Chemistry
Title: Current Treatments of Primary Sclerosing Cholangitis
Volume: 14 Issue: 19
Author(s): M. Vacca, M. Krawczyk, M. Petruzzelli, R.C. Sasso, K.J. van Erpecum, G. Palasciano, G.P. vanBerge-Henegouwen, A. Moschetta and P. Portincasa
Affiliation:
Keywords: Liver, cirrhosis, inflammation, UDCA, immunosuppressant, IBD, cholestasis, biliary obstruction
Abstract: Primary Sclerosing Cholangitis (PSC) is a chronic cholestatic disease characterized by hepatic inflammation and obliterative fibrosis, resulting in both intra- and extra-hepatic bile duct strictures. End-stage liver disease and bile duct carcinoma represent frequent complications. Incidence and prevalence of PSC in USA have been recently estimated as 0.9 per 100,000 person-years, and 1-6 per 100,000 person-years, respectively. Major diagnostic criteria include the presence of multifocal strictures, beadings of bile ducts, and compatible biochemical profile, once excluded secondary causes of cholangitis. Since the aetiology of PSC remains poorly defined, medical therapy is currently limited to symptom improvement and prolonged survival. Ursodeoxycholic acid (UDCA), corticosteroids and immunosuppressants have been proposed alone or in combination to improve the clinical outcome. In selected cases, surgical or endoscopic procedures need to be considered. Orthotopic liver transplantation (OLT) is at the moment the only definitive approach although disease relapse has been reported In this article the state of the art in PSC treatment and future promises in this field are reviewed.
Export Options
About this article
Cite this article as:
M. Vacca , M. Krawczyk , M. Petruzzelli , R.C. Sasso , K.J. van Erpecum , G. Palasciano , G.P. vanBerge-Henegouwen , A. Moschetta and P. Portincasa , Current Treatments of Primary Sclerosing Cholangitis, Current Medicinal Chemistry 2007; 14 (19) . https://dx.doi.org/10.2174/092986707781368388
DOI https://dx.doi.org/10.2174/092986707781368388 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Separation of Ginseng Active Ingredients and their Roles in Cancer Metastasis Supplementary Therapy
Current Drug Metabolism Pathophysiological Role of Hepatocyte Nuclear Factor 6 in Negative Regulation of Hepatic Apoptosis: A Novel Hypothesis
Current Molecular Medicine Meet Our Regional Editor
Anti-Cancer Agents in Medicinal Chemistry Membrane Targeted Chemotherapy with Hybrid Liposomes for Tumor Cells Leading to Apoptosis
Current Pharmaceutical Design Inflammatory Bowel Disease and Celiac Disease: Overlaps in the Pathology and Genetics, and their Potential Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets Bilirubin Chemistry and Metabolism; Harmful and Protective Aspects
Current Pharmaceutical Design ATP-Binding Cassette Efflux Transporters in Human Placenta
Current Pharmaceutical Biotechnology Melatonin, a Potential Therapeutic Agent for Smooth Muscle-Related Pathological Conditions and Aging
Current Medicinal Chemistry A Synopsis on the Role of Human Papilloma Virus Infection in Cervical Cancer
Current Drug Metabolism CCR5 as a Potential Target in Cancer Therapy: Inhibition or Stimulation?
Anti-Cancer Agents in Medicinal Chemistry The Effect of Alcohol on Gastrointestinal Motility
Reviews on Recent Clinical Trials Decreased lncRNA SNHG16 Accelerates Oxidative Stress Induced Pathological Angiogenesis in Human Retinal Microvascular Endothelial Cells by Regulating miR-195/mfn2 Axis
Current Pharmaceutical Design Diabetic Gastroenteropathy: Soothe the Symptoms or Unravel a Cure?
Current Diabetes Reviews Trefoil Factor Family (TFF) Peptides and their Different Roles in the Mucosal Innate Immune Defense and More: An Update
Current Medicinal Chemistry Strategies for Design of Non Peptide CCK1R Agonist/Antagonist Ligands
Current Topics in Medicinal Chemistry Biliary Innate Immunity in the Pathogenesis of Biliary Diseases
Inflammation & Allergy - Drug Targets (Discontinued) The Functions of Heparanase in Human Diseases
Mini-Reviews in Medicinal Chemistry A Cross Sectional Study of Tumors Using Bio-Medical Imaging Modalities
Current Medical Imaging Redox Homeostasis, Bioactive Agents and Transduction Therapy
Current Signal Transduction Therapy Ferroptosis: A Novel Mechanism of Artemisinin and its Derivatives in Cancer Therapy
Current Medicinal Chemistry